News
Tirzepatide use vs placebo was associated with slower decline in eGFR among patients with prediabetes and obesity or overweight.
Powerful new medications such as Ozempic and Mounjaro, known as GLP-1 drugs are helping to win the war against obesity in ...
Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...
Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, ...
Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results